CLINICAL_TRIALS
other
· 2024-05-23
Clinical Trial Update: Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma [Phase 3]
Summary
Phase 3 adjuvant trial of nivolumab for high-risk Stage II melanoma is currently active but not recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University Hospital, Essen | Conditions: Malignant Melanoma Stage II | Phase 3 | Status: ACTIVE_NOT_RECRUITING